KNSA 240816 22.50C (KNSA240816C22500) Stock Options, News & Quotes

US OptionsDetailed Quotes

KNSA240816C22500

Watchlist

4.03
+2.68+198.52%

15min DelayClose Jul 24 15:59 ET

4.03High4.03Low

Intraday

5D
Daily

News

Kiniksa Pharmaceuticals International And Two More Firms Possibly Priced Below Market Value Estimates
Yahoo FinanceJul 24 09:07 ET
There's No Escaping Kiniksa Pharmaceuticals International, Plc's (NASDAQ:KNSA) Muted Revenues Despite A 41% Share Price Rise
Simply Wall StJul 24 08:47 ET
Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $30
Moomoo NewsJul 24 08:33 ET · Ratings
Express News | Kiniksa Pharmaceuticals Ltd. : Wells Fargo Raises Target Price to $35 From $34
ReutersJul 24 06:48 ET
Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $35
Moomoo NewsJul 24 05:32 ET · Ratings
Earnings Call Summary | Kiniksa Pharmaceuticals International(KNSA.US) Q2 2024 Earnings Conference
moomoo AIJul 24 05:11 ET · Conference Call

Comments

TrendTrader

Yesterday 00:19

Looking for 30

$Kiniksa Pharmaceuticals International(KNSA.US)$

Moomoo AI

Feb 28 07:16

The share price rise is a fair reaction to the company's revenue growth. More gains could follow if the trend continues. Yet, consider the company's profitability and cash flow before investing.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Delivers Shareholders Respectable 66% Return Over 1 Year, Surging 4.7% in the Last Week Alone

Moomoo AI

Jan 23 06:38

Kiniksa Pharmaceuticals' low P/S ratio may be due to its forecast growth being lower than the industry. Shareholders accept this, conceding future revenue probably won't surprise positively. It's hard to see the share price rising strongly soon under these circumstances.

Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Low P/S No Reason For Excitement

Meltyy

Jan 3 06:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences(CLRB.US)$ Phase 2
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...

Moomoo AI

Dec 8, 2023 10:12

Kiniksa Pharmaceuticals' growing cash burn is offset by substantial cash reserves & signs of business growth. The firm can issue shares or borrow cheaply to fund further growth.

We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn